About: Nanoengineering of vaccines using natural polysaccharides

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nanoengineering of vaccines using natural polysaccharides Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Nanoengineering of vaccines using natural polysaccharides
Creator	Alonso, José Cordeiro, Ana De La Fuente, María
Source	Elsevier; Medline; PMC
abstract	Abstract Currently, there are over 70 licensed vaccines, which prevent the pathogenesis of around 30 viruses and bacteria. Nevertheless, there are still important challenges in this area, which include the development of more active, non-invasive, and thermo-resistant vaccines. Important biotechnological advances have led to safer subunit antigens, such as proteins, peptides, and nucleic acids. However, their limited immunogenicity has demanded potent adjuvants that can strengthen the immune response. Particulate nanocarriers hold a high potential as adjuvants in vaccination. Due to their pathogen-like size and structure, they can enhance immune responses by mimicking the natural infection process. Additionally, they can be tailored for non-invasive mucosal administration (needle-free vaccination), and control the delivery of the associated antigens to a specific location and for prolonged times, opening room for single-dose vaccination. Moreover, they allow co-association of immunostimulatory molecules to improve the overall adjuvant capacity. The natural and ubiquitous character of polysaccharides, together with their intrinsic immunomodulating properties, their biocompatibility, and biodegradability, justify their interest in the engineering of nanovaccines. In this review, we aim to provide a state-of-the-art overview regarding the application of nanotechnology in vaccine delivery, with a focus on the most recent advances in the development and application of polysaccharide-based antigen nanocarriers.
has issue date	2015-11-01(xsd:dateTime)
bibo:doi	10.1016/j.biotechadv.2015.05.010
bibo:pmid	26049133
has license	els-covid
sha1sum (hex)	ae90c817f26e02354fbc4944059f132f32395285
schema:url	https://doi.org/10.1016/j.biotechadv.2015.05.010
resource representing a document's title	Nanoengineering of vaccines using natural polysaccharides
has PubMed Central identifier	PMC7127432
has PubMed identifier	26049133
schema:publication	Biotechnology Advances
resource representing a document's body	covid:ae90c817f26e02354fbc4944059f132f32395285#body_text
is schema:about of	named entity 'advances' named entity 'vaccination' named entity 'subunit' named entity 'nanocarriers' named entity 'immune responses' named entity 'polysaccharides' named entity 'CHARACTER' named entity 'SIZE' named entity 'MOST RECENT' named entity 'PARTICULATE' named entity 'ART' named entity 'CAPACITY' named entity 'PROTEINS' named entity 'ROOM' named entity 'HOLD' named entity 'LOCATION' named entity 'LED' named entity 'INTRINSIC' named entity 'IMMUNOGENICITY' named entity 'DEVELOPMENT' named entity 'VACCINATION' named entity 'FOCUS' named entity 'BASED' named entity 'ASSOCIATION' named entity 'THEIR' named entity 'RESISTANT' named entity 'HIGH' named entity 'INFECTION PROCESS' named entity 'DELIVERY' named entity 'SPECIFIC' named entity 'NANOENGINEERING' named entity 'NATURAL' named entity 'VACCINES' named entity 'OVERVIEW' named entity 'SUBUNIT' named entity 'MOLECULES' named entity 'DOSE' named entity 'ADJUVANT' named entity 'DUE TO' named entity 'ANTIGEN' named entity 'CHALLENGES' named entity 'PROLONGED' named entity 'PROPERTIES' named entity 'LICENSED' named entity 'NON-INVASIVE' named entity 'VACCINE DELIVERY' named entity 'ALLOW' named entity 'STRUCTURE' named entity 'ACTIVE' named entity 'INCLUDE' named entity 'HAVE' named entity 'NATURAL' named entity 'LIKE' named entity 'MUCOSAL' named entity 'ANTIGENS' named entity 'TIMES' named entity 'IMPORTANT' named entity 'LIMITED' named entity 'POLYSACCHARIDES' named entity 'POLYSACCHARIDES' named entity 'ADJUVANTS' named entity 'POTENTIAL' named entity 'PATHOGENESIS' named entity 'BIOCOMPATIBILITY' named entity 'NUCLEIC ACIDS' named entity 'USING' named entity 'NANOTECHNOLOGY' named entity 'PREVENT' named entity 'UBIQUITOUS' named entity 'ADMINISTRATION' named entity 'INTEREST' named entity 'TAILORED' named entity 'OVERALL' named entity 'AIM' named entity 'VACCINES' named entity 'ENHANCE' named entity 'OF-' named entity 'POLYSACCHARIDE' named entity 'IMMUNE RESPONSE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software